British pharmaceutical company increases productivity by optimising its powder screening process with Russell Finex's Vibrasonic Deblinding System
GlaxoSmithKline is improving process efficiency in the production of pharmaceutical powders at its 'centre of excellence' plant in Dartford, Kent, by investing in nine new high performance vibrating sieves fitted with the Vibrasonic Deblinding System from Russell Finex.
Many of the pharmaceutical powders produced at the plant are difficult to screen efficiently due to mesh blinding and because they are low density and gain static. Instead of passing easily through a conventional separator they tend to float above the mesh, slowing down production and reducing efficiency.
The Vibrasonic Deblinding System has solved these problems, significantly increasing productivity as well as reducing costs and meeting GlaxoSmithKline's HACCP and due diligence requirements. The separators are used at the final stage of primary manufacture, screening the pharmaceutical powders to the required size before they are sent away for the second manufacturing stage, when the powders are made either into tablets or a liquid suspension. The Vibrasonic 2000 also gives greater control over the mesh and powder settings to increase throughput of static powders. The strength and duration of the ultrasonic activity can be tailored to suit the particular production run. GlaxoSmithKline use the pulse facility, the ultrasonic frequency, switching it on and off at pre-set intervals to allow the powder to fall through the screen instead of floating above it. This maintains a consistently high throughput.
Contact Russell Finex to speak to a sales engineer about your requirements.